Visualization of choline-containing phospholipids in cells and in vivo is made possible by the metabolic incorporation of a choline analog with an alkyne handle for click chemistry–based labeling.

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...

Disorders in endogenous lipid metabolism have been associated with ... amyloid-β and tau, and phospholipids, sphingolipids, cholesterol and oxysterols as representatives of membrane lipids ...

Anglia Ruskin University (ARU) in Cambridge, England, has teamed up with Norwegian biotech company Arctic Bioscience to conduct the largest research project to date on the health benefits of omega-3 ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...